This page provides up-to-date information about
antiangiogenesis research, including an update on the drug endostatin, along
with a listing of agents currently in clinical trials.
Angiogenesis
Inhibitors in Clinical Trials(updated 12/06/99) This
series of tables lists agents currently in Phase I, II, and III trials, with
contact information for each trial.
NCI's
Role in the Development of Endostatin(posted 09/15/99) A
Sept. 13, 1999, report in the Wall Street Journal stated incorrectly that
National Cancer Institute (NCI) scientists have "failed" to replicate findings
showing that the antiangiogenesis compound endostatin can dramatically shrink
tumors in mice.
Angiogenesis
Inhibitors in Cancer Research(updated 03/31/99) This fact
sheet provides an overview of anti-angiogenesis research, including a look at
the science, the strategies researchers are using, and how this type of
therapy compares to standard chemotherapy in some cases.
Anti-Angiogenesis Archive
NCI
and Sugen to collaborate on development of anti-cancer agent(posted 04/04/99) The National Cancer Institute has signed a clinical
trials agreement with Sugen, Inc. to collaborate on the development of
SU5416, an inhibitor of angiogenesis that has been shown to inhibit the
growth of tumors in mice. Additional information about SU5416 can also be
obtained from the manufacturer at www.sugen.com or 1-800-SUGEN-06.
